ClinicalTrials.gg
RecruitingNCT04063631Updated Jan 9, 2024

Pulmonary Epithelium, Immunology and Development of Asthma: Breathing Together

An observational study in Asthma and Wheezing, sponsored by Imperial College London. Recruiting at 1 site in United Kingdom. Open to participants aged 5 Days to 16 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-01-09.

Sponsored by Imperial College London · Observational

How we know

From the registry’s dates

  • Primary completion was expected by Sep 2024, 2 years 2 months ago, but the record still lists the study as recruiting.
  • Started Feb 2017; still recruiting 9 years 9 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Other
Time perspective
Other
Enrollment
1,300
Ages
5 Days to 16 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 46 studies in Asthma by Imperial College London — 4 open to participants now, 4 under way, none of them phase 3. Asthma · Imperial College London.

Planned enrollment
Largest of 17
1,300 · median 66
Started
2017
with 1 other
Observational
17 of 46
4 open now
Registered
39th of 46
by date

Among the 46 studies in Asthma by Imperial College London, this one has the largest planned enrollment of the 17 observational ones that give a count, is one of 2 that started in 2017, is one of 17 observational ones, and was the 39th registered.

Asthma

4,850 studies on the registry are indexed under Asthma; 604 are open to participants now.

Browse Asthma studies →

Open to participants now

4 of the 46 studies in Asthma by Imperial College London are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Where they have run

Who these studies take

Of the 416 Asthma studies recruiting now, 141 (34%) set no upper age limit and 204 (49%) stop at 75 or younger; 146 take children under 18; 105 take healthy volunteers.

This study: 5 Days to 16 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 46 studies in Asthma by Imperial College London, or all of them as a file.
02

Study summary

The investigators want to know why some babies wheeze and some of these go on to develop asthma. The investigators are going to find out if babies who develop wheeze and asthma have abnormal airway lining cells (taken from the nose) when they are born and what happens to these cells as they get older.

The study will last three years. Parents will be asked to fill in a monthly health questionnaire. The tests on the babies are all in routine clinical use: a urine sample, a blood test from a heel or finger prick, swabs from the nose and throat to look at the microbiome, and a brushing of cells from the inside of the nose. These tests will be performed at 5-10 days old, and at one and three years. Parents will be asked to fill in online monthly health questionnaire. Some babies will have the swabs repeated at 3 and 6 months, and those who wheeze in the first 3 years of life, samples during the illness and after recovery.

Read the detailed description

The cells that line the airways act as a barrier to infections and proteins that cause allergy, and also release a host of signalling molecules. It known that these airway cells in children with established asthma react abnormally to viruses, but not known if this is cause or consequence of asthma. Also, little is known about how the immune system develops in new born babies and how it responds to the bacteria which they meet.

This research arises from a £4.64 million Wellcome Trust strategic award. The importance of the underlying question was established with by the investigators, and the grant was developed by the collaborators at an all-day meeting followed by further telephone conferences. The Wellcome Trust also guided the development of the grant, it was peer-reviewed, it was interviewed after answering a series of questions from the referees, and subsequent to the interview, a further set of questions were answered before the Award letter was issued.

The overarching research hypothesis is that babies who develop asthma have abnormal epithelial function at birth, which further deviates from normal during the first 3 years of life. The vision is to understand what initiates asthma; facilitate development of biomarkers predicting progression of preschool wheeze to asthma; and eventually, outwith this study (in which there is no therapeutic intervention), design randomised controlled trials targeted at high risk children. The ultimate goal is preventing asthma initiation and improving lifelong lung health.

Asthma is predominantly a childhood onset disease affecting over 300 million people worldwide, and over a million children in the United Kingdom. At birth, babies who subsequently wheeze have airflow obstruction and altered immune responses. Babies who will develop asthma have airflow obstruction at birth, which worsens to age six. Thereafter, all birth cohorts have shown that lung function tracks, one of the longest (Melbourne) going on into the sixth decade of life. The first six years of life are therefore critical in determining adult lung function. Mouse data suggest that airway epithelial function is abnormal but translational evidence is lacking. Genetic and environmental factors are important in evolution of wheeze. Viral infection is a major cause of acute wheeze, but bacteria are at least as important, and early bacterial colonisation is associated with abnormal mucosal immunology. An abnormal airway microbiome skews systemic immunity to an allergic phenotype. The airway is no mere passive barrier, but also secretes innate cytokines, e.g. IL-33, which are implicated in early wheeze. Aeroallergen sensitization in the first 4 years of life, but not thereafter, is strongly predictive of subsequent asthma. Taken together, this suggests that understanding developmental changes in epithelial functions, and interactions with genes, immunity and pathogens, are crucial if progression to asthma is to be halted. The first 4 years of life represent a unique window during which adverse effects have irreversible consequences. However, understanding of the developing immune system and underlying epithelial-immune interactions during this critical period is very superficial, and it is this which the present application addresses. A significant limitation of all birth cohorts to date is the absence of airway epithelial samples to determine the mechanisms that underlie the development of early airflow obstruction and identify molecular targets for disease prevention. This project will be the first to investigate the three way interactions between airway epithelial cell function, immune responses and airway microbiota in the first four years of life to elicit the mechanisms underlying the development of preschool wheeze and its progression to asthma. The vision is to understand what initiates asthma; facilitate development of biomarkers predicting progression of pre-school wheeze to asthma; and ultimately, design interventions targeted only at high risk children, evaluated in randomised controlled trials outwith this grant. The ultimate goal is preventing asthma initiation and improvement of lifelong lung health.

Key research questions are:

  1. How does epithelial function evolve from birth to 3 years in children who develop asthma, and how does the epithelium interact with the evolving immune system and airway microbiome?
  2. What are the mechanisms whereby pathogens and aeroallergens modulate epithelial-immune interactions, skewing airway responses towards asthma rather than resolution?
  3. Can these pathways be used to identify biomarkers of asthma development, enabling future preventive strategies?

The aims are:

  1. To establish uniform clinical phenotyping and protocols for longitudinal and prospective sample acquisition
  2. To utilise bioinformatics and systems biology to identify phenotypic clusters
  3. To utilise an integrated clinical/basic science (systems based) approach to investigate molecular interactions between respiratory epithelium, genetics, infections, and the developing immune system and airway microbiome.

Specific objectives are:

  1. Recruit newborn babies with detailed antenatal history, and obtain nasal epithelial cells at one week of age, and follow them longitudinally for three years with serial sampling, retrospectively phenotyping them depending on whether they develop wheeze or not.
  2. Compare the evolving changes in immune and epithelial function in this group with the pathobiology of established mild and severe wheezers.
  3. Use these samples to understand the normal and abnormal developmental interactions between the airway epithelium, the host immune system and the airway microbiome.
  4. Utilize the rich longitudinal data on childhood wheezing, relevant biomarkers and genetics assembled through the birth cohorts to model the biological complexity of preschool wheezing and generate hypotheses that can be tested in vitro in age- appropriate epithelial cell cultures
03

Conditions studied

  • Asthma
  • Wheezing

Keywords

  • Asthma
04

Who can participate

Ages eligible
5 Days to 16 Years
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Probability sample

Study population

Singleton neonates with the developing wheeze in the before their third birthday and young children (≤5 years) with a history of mild to moderate wheezing, and those without previous wheezing.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • expectant mother or infant aged 0-10 days
  • children with recurrent wheezing and other clinical atopy
  • children with recurrent wheezing and no obvious wheezing triggered by aeroallergens and no clinical evidence of other atopy.
  • children with no history of wheezing but with at least one clinically apparent atopic disorder
  • children with no history of wheezing and with no clinical evidence of other atopic disorder
  • all children will be undergoing an elective surgical procedure
  • all children will have been born at term (37-42 weeks gestation)
  • the anaesthetist will have deemed the child fit for elective surgery, free from a recent respiratory tract infection, stable and suitable for the research study samples to be taken.
  • in the case of blind non-bronchoscopic sample suitable for endotracheal intubation or for a fibre-optic bronchoscopy if this is the chosen method of sampling

Exclusion criteria

Exclusion Criteria:

  • pre-term infants (\<37 weeks gestation)
  • twins or other multiples
  • maternal group B streptococcus on high vaginal swab in the present pregnancy
  • need for CPAP or ventilatory support in the neonatal period
  • infants with major concurrent health problems, e.g. congenital heart disease, cystic fibrosis, those requiring special feeding regimens on account of prematurity or illness
  • infants who will not be available to assess acutely if they develop wheeze
  • infants who are likely to move away from the study centre before 3 years of age
  • children with a recent respiratory tract illness (should have recovered > 2 weeks)
  • children with other major respiratory illnesses such as and including Cystic Fibrosis, Chronic Neonatal Lung Disease, pulmonary aspiration syndromes.
  • children with evidence of a systemic inflammatory or infective condition
  • children with a history of previous pituitary or ethmoid surgery
05

Study design

Observational model
Other
Time perspective
Other
Enrollment
1,300 participants (estimated)
Patient registry
No
Biospecimen retention
Samples with dna

Groups and cohorts

  • 1/Birth cohort

    Prospective, longitudinal cohort of 1000 healthy infants. Recruited at birth and followed for 3 years. Samples to be collected at 5-10 days old, 1 and 3 years old. 100 participants with additional samples collected at 3 and 6 months of age. Approximately 300 participants to have samples collected at time of active wheezing and during convalescence.

  • 2/mild wheezers and controls

    Children under 5 years old undergoing elective general surgical procedure. Some will have mild-to-moderate wheeze while others will be non-wheezing controls

  • 3/pre-school aged severe wheezers

    50 children aged 1-6 years undergoing clinically indicated bronchoscopy due to recurrent wheezing.

  • 4/school aged severe asthmatics

    50 kids aged 6-16 undergoing clinically indicated bronchoscopy due to asthma.

06

What researchers measure

Primary outcomes

  1. Changes on airway epithelium cells assessed by cell biology tools

    To detect the airway epithelium cells differences between onset of wheeze, wheezers and non-wheezers with swabs from the nose

    Time frame: 3 years

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2017 (actual). Primary completion is estimated for Sep 2024, 90 months after the start.

Of 366 non-industry observational studies under Asthma, half reached primary completion within 38 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 97. This study's planned 90 months is above that.

Counting every sponsor, half of 456 studies reached it within 36 months; a quarter within 18 and three quarters within 82.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 7, 2019
First posted
Aug 21, 2019
StartActual
Feb 20, 2017
Primary completionEst.
Sep 18, 2024
CompletionEst.
Sep 18, 2024
Last update
Jan 9, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 9, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04063631
Responsible party
Sponsor
First posted
Aug 21, 2019
Start date
Feb 20, 2017
Primary completion
Sep 18, 2024 (estimated)
Completion
Sep 18, 2024 (estimated)
Last update
Jan 9, 2024

Study contacts

Mindy L Gore, PhD
Contact
m.gore@imperial.ac.uk
+442075946857
Andrew Bush, MD
principal investigator · Imperial College London

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion